PMID int64 35.7M 36.4M | Title/Abstract stringlengths 22 8.78k | MeshTerms stringlengths 7 101 | SemanticTypes stringlengths 4 64 |
|---|---|---|---|
36,253,400 | preval clinic signific anatom variant cephal arch preoper map venographi aim current studi determin preval anatom variant cephal arch preoper map venographi evalu patenc rate predictor patenc patient brachiocephal fistula preval anatom variant cephal arch retrospect evalu consecut patient underw bilater preoper map venographi juli decemb singl center overal preval anatom variant cephal arch patenc analysi patient brachiocephal fistula divid two group standard anatomi sa group n variant anatomi va group n signific differ clinic characterist two group primari patenc rate differ signific two group secondari patenc rate signific p lower va group sa group older age hr ci p negat predictor primari patenc antiplatelet agent hr ci p larg diamet cephal vein hr ci p posit predictor primari patenc older age hr ci p anatom variant cephal arch hr ci p negat predictor secondari patenc current studi provid insight clinic signific anatom variant cephal arch anatom variant cephal arch consid potenti risk factor decreas patenc brachiocephal fistula preoper plan | D001166 | T061 |
36,253,398 | tensil strain alter synovi tissu metabol human knee osteoarthr synovium critic maintain joint homeostasi may contribut mechanobiolog respons joint movement investig mechanobiolog respons whole synovium patient late stage knee osteoarthr oa synovium sampl collect total knee arthroplasti assign histopatholog cyclic tensil strain load includ static control low frequenc hz iii high frequenc hz min h incub tissu bisect rna isol immunostain nitrotyrosin nt rna sequenc analyz differenti express gene pathway enrich cytokin lactat measur condit media compar control low frequenc strain induc enrich pathway relat interferon respons fc receptor signal cell metabol high frequenc strain induc enrich pathway relat nod like receptor signal high metabol demand redox signalingstress metabol redox cell stress confirm increas releas lactat condit media increas nt format synovi line late stage oa synovi tissu respons tensil strain includ frequenc depend increas inflammatori signal metabol redox biolog base find specul synovi mechanobiolog respons strain may benefici oa like disturb synovi homeostasi lead aberr respons mechan stimuli requir valid | D020370 | T047 |
36,253,396 | interconnect marin habitat form singl continent scale reef system south america larg gap reef distribut may hinder dispers marin organ interrupt process vital mainten biodivers show presenc locat extens reef habitat continent shelf amazon reef system ar eastern brazilian reef system er two reef complex eastern south america format locat deep includ biogen geogen structur presenc divers reef assemblag suggest widespread occurr rocki substrat habitat repres expans ar er closur remain larg scale gap km among west atlant reef environ indic sw atlant harbor singl yet heterogen reef system stretch km thus repres one largest semi continu tropic marin ecosystem world | D044822;D017753 | T070;T082;T080 |
36,253,395 | impact bodi weight chang clinic outcom patient idiopath pulmonari fibrosi receiv pirfenidon limit studi associ prognosi bodi weight chang patient idiopath pulmonari fibrosi ipf singl center retrospect observ studi evalu impact weight loss outcom korean patient ipf receiv pirfenidon tertiari medic institut analyz ipf patient prescrib pirfenidon januari st decemb st patient categor maintain weight mw weight gain loss year reduc weight rw weight loss year group mean age year male patient rw group patient show decreas bodi weight baselin vs year kg vs kg p although baselin lung function show differ differ rate chang forc vital capac predict p diffus capac lung carbon monoxid predict p mw group lower risk caus mortal p weight loss appear signific risk factor mortal patient ipf diseas control antifibrot agent also effort prevent weight loss may necessari | D054990 | T047 |
36,253,394 | digit platform design patient centric suppli chain chimer antigen receptor car cell therapi receiv increas attent show promis result treatment acut lymphoblast leukaemia aggress b cell lymphoma unlik typic cancer treatment autolog car cell therapi patient specif make uniqu therapeut manufactur distribut work focus develop comput model tool assist design assess suppli chain structur reliabl cost effici deliv autolog car cell therapi focus four demand scale patient annual assess tool capabl respect design respons suppli chain candid solut minimis cost | D016393;D054198;D000076962 | T129;T191;T116;T192 |
36,253,393 | mhd flow time fraction casson nanofluid use general fourier fick law inclin channel applic gold nanoparticl gold nanoparticl common use tracer laboratori biocompat transport heat energi tumor cell via varieti clinic techniqu cancer cell tini proper size nanoparticl introduc circul invas result gold nanoparticl high effect therefor current research investig magnetohydrodynam free convect flow casson nanofluid inclin channel blood consid base fluid gold nanoparticl assum uniform dispers flow regim formul term partial differenti equat system deriv equat impos boundari condit non dimension use appropri dimensionless variabl fourier fick law use fraction classic dimensionless model laplac fourier sine transform new transform use close form solut consid problem final result express term specif function known mittag leffler function various figur tabl present effect various physic paramet achiev result graphic result conclud fraction casson fluid model describ realist aspect fluid veloc profil temperatur concentr profil classic casson fluid model heat transfer rate sherwood number calcul present tabular form worth note increas volum percentag gold nanoparticl percent result increas heat transfer rate | D006046;D053768 | T121;T196;T073 |
36,253,392 | heat tobacco product circul high densiti lipoprotein cholesterol concentr aim assess associ heat tobacco product htp use high densiti lipoprotein cholesterol hdl c concentr studi includ worker five compani studi worker anoth larg compani studi ii particip categor five group never smoker past smoker exclus htp user dual user cigarett htps exclus cigarett smoker analyz data studi ii separ pool estim use fix effect model particip exclus htp user dual user exclus htp user modest signific lower concentr hdl c never smoker pool mean differ ci mgdl dual user show reduct mean differ mgdl compar exclus cigarett smoker versus never smoker mean differ mgdl pool odd ratio cis low hdl c mgdl men mgdl women never smoker past smoker exclus htp user dual user exclus cigarett smoker respect conclus exclus htp user lower hdl c concentr never smoker although higher exclus cigarett smoker moreov dual user hdl c concentr similar exclus cigarett smoker | D066300;D062789 | T131;T073;T109 |
36,253,391 | characterist hospit patient sar cov infect success wave covid pandem refer hospit spain sinc begin covid pandem septemb spain suffer five wave infect latter relat expans delta variant high incid vaccin campaign began decemb end fifth wave peopl fulli vaccin examin chang dynam covid pandem impact outcom among hospit essenti object ascertain differ characterist outcom hospit patient period compar previous wave prospect enrol consecut admit hospit patient wave collect clinic demograph data medic record includ symptom comorbid death whether need admit intens care unit receiv assist ventil found patient fifth wave consider younger mortal rate fell admiss intens care unit decreas patient fifth wave fewer comorbid age patient die higher surviv result show mark improv patient outcom fifth wave suggest success vaccin campaign despit explos case due delta variant | D000086382 | T047;T067 |
36,253,390 | human trpa intrins cold heat sensit involv separ channel structur beyond n ard domain trp channel sens temperatur rang noxious cold noxious heat whether special trp thermosensor modul exist control channel pore gate unknown studi purifi human trpa htrpa truncat protein gain insight temperatur gate htrpa patch clamp bilay record htrpa without n termin ankyrin repeat domain n ard sensit cold heat wherea htrpa also lack voltag sens like domain vsld gain sensit cold lost heat sensit htrpa intrins tryptophan fluoresc studi cold heat evok rearrang vsld c terminus domain distal transmembran pore domain ctd whole cell electrophysiolog experi replac ctd locat cystein alanin modul htrpa cold respons propos htrpa ctd harbor cold heat sensit domain alloster coupl pore region vsld respect | D017089;D006358 | T070;T116;T044 |
36,253,388 | hydrodynam condit affect proteom profil marin biofilm form filament cyanobacterium proteom studi cyanobacteri biofilm effect approach unravel metabol pathway involv biofilm format consequ obtain effici biofoul control strategi biofilm develop filament cyanobacterium toxifilum sp lege evalu differ surfac glass perspex two signific shear rate marin environ higher biofilm develop observ overal protein identifi differ proteom notic hydrodynam condit found surfac twenti differenti express protein dep found vs glass dep includ phage tail protein carotenoid protein cyanophynas glutathion depend formaldehyd dehydrogenas moadthi famili protein perspex dep includ transketolas dihydroxi acid dehydratas iron abc transport substrat bind protein protein nusg studi contribut develop standard protocol proteom analysi filament cyanobacteri biofilm kind proteom analysi also use differ research field given broad spectrum promis secondari metabolit ad valu compound produc cyanobacteria well develop new antibiofilm strategi | D000458;D057446 | T007;T070 |
36,253,384 | optim method purifi detect quantifi mycobacterium tuberculosi rna sputum monitor treatment respons tb patient diagnost accur detect quantifi viabl mycobacterium tuberculosi mtb sputum patient undergo therapi need current cultur molecular base test shown limit efficaci monitor treatment respons tb patient either due presenc viabl sub popul mtb fail grow standard cultur condit term differenti detectablecultur mtb dd mtb prolong half life mtb dna sputum report optim rna base method detect quantifi viabl mtb patient sputum cours therapi first empir deriv novel rna extract protocol sputum improv recoveri mtb rna almost complet elimin contamin mtb dna host nucleic acid next identifi five mtb rrna primer set vari limit detect capabl distinguish live versus dead hrv mtb combin protocol test sputa longitudin cohort patient receiv therapi drug sensit ds drug resist dr tb first line second line regimen respect result compar cultur includ cfu bactec mgit limit dilut assay capabl detect dd mtb five rrna primer set posit identifi near rang cultur posit sputa portion cultur negat sputa comparison ten high express mtb mrnas show posit cultur posit sputa cultur negat sputa two five rrna primer set abl posit identifi cultur posit sputa test cultur negat sputa ds cohort month post initi therapi identifi sampl posit percentag line expect treatment failur rate first line therapi discontinu earli two primer set also detect rrna sputa month post initi therapi dr cohort cycl threshold valu rrna show strong correl mtb number determin cultur r includ mtb number declin cours treatment first line second line regimen optim molecular assay outlin may util monitor treatment respons tb patient | D009169;D014388;D014397 | T047;T007 |
36,253,382 | generaliz deep learn model earli alzheim diseas detect structur mris earli diagnosi alzheim diseas play pivot role patient care clinic trial studi develop new approach base deep convolut neural network accur differenti mild alzheim diseas dementia mild cognit impair cognit normal individu use structur mris comparison built refer model base volum thick previous report brain region known implic diseas progress valid model intern held cohort alzheim diseas neuroimag initi adni extern independ cohort nation alzheim coordin center nacc deep learn model accur achiev area curv auc distinguish cognit normal subject subject either mci mild alzheim dementia challeng task detect mci achiev auc also signific faster volumethick model volum thick need extract beforehand model also use forecast progress subject mild cognit impair misclassifi mild alzheim diseas dementia model faster progress dementia time analysi featur learn propos model show reli wide rang region associ alzheim diseas find suggest deep neural network automat learn identifi imag biomark predict alzheim diseas leverag achiev accur earli detect diseas | D000544;D060825;D000077321 | T047;T066;T048 |
36,253,381 | mammalian n adenosin paryl revers dna modif poli adp ribosyl paryl regard protein specif modif howev parp recent shown modifi dna termini vitro use ultrasensit mass spectrometri lc msms anti par antibodi anti par reagent show mammalian dna physiolog paryl differ level primari tissu inhibit par glycohydrolas parg increas dna paryl support modif revers dna paryl requir parp vitro parp paryl singl strand dna parg revert modif dna paryl occur n posit adenosin residu form n poli adp ribosyl deoxyadenosin partial hydrolysi mammalian gdna identifi par dna via diagnost deamin product n ribosyl deoxyinosin occur vivo discoveri n adenosin paryl dna modif establish conceptu methodolog framework elucid biolog relev extend role parp enzym | D000074747;D000067856 | T121;T044 |
36,253,380 | effect weiss ring peripapillari retin nerv fiber layer thick measur use sd oct spectral domain optic coher tomographi sd oct must accur identifi measur peripapillari retin nerv fiber layer prnfl thick improv repeat reproduc reduc measur error weiss ring locat front optic disc hypothes may affect prnfl thick measur obtain use sd oct retrospect review medic record patient group w without group n weiss ring observ oct fundus imag rnfl map devis use sd oct optic disc cube scan obtain measur prnfl thick superior tempor inferior nasal averag two consecut visit pearson correl coeffici r intraclass correl coeffici icc coeffici variat cv calcul r icc valu prnfl thick measur two visit lower group w compar group n statist signific reach inferior prnfl thick addit cv valu greater group w compar group n differ signific inferior averag prnfl thick measur p p respect weiss ring locat near optic disc affect prnfl thick measur repeat thereof especi inferior quadrant averag valu therefor import identifi presenc weiss ring analyz prnfl thick valu | D009412;D041623 | T026;T060;T023 |
36,253,379 | onlin singl cell data integr project heterogen dataset common cell embed space comput tool integr analys divers singl cell experi face formid new challeng includ dramat increas data scale sampl heterogen need inform cross refer new data foundat dataset present scalex deep learn method integr singl cell data project cell batch invari common cell embed space truli onlin manner ie without retrain model scalex substanti outperform onlin inmf state art non onlin integr method benchmark singl cell dataset divers modal eg singl cell rna sequenc scrna seq singl cell assay transposas access chromatin use sequenc scatac seq especi dataset partial overlap accur align similar cell popul retain true biolog differ showcas scalex advantag construct continu expand singl cell atlas human mous covid patient assembl divers data sourc grow everi new data onlin data integr capac superior perform make scalex particular appropri larg scale singl cell applic build upon previous scientif insight | D000086382;D059010 | T047;T059;T067 |
36,253,378 | systemat review associ sleep disord breath cardiovascular patholog adult sleep disord breath sdb character repeat breath paus sleep preval sdb vari wide studi longitudin studi found associ sdb incid recurr cardiovascular event sought systemat describ current data correl sdb cardiovascular patholog studi includ origin observ popul base studi adult clear diagnos sdb primari outcom includ type cardiovascular patholog carri pool analys use random effect model systemat review perform accord prisma moos guidelin systemat review regist prospero total articl detect databas articl chosen full text review fourteen studi focus sampl unselect popul studi focus group person risk sdb studi incid cardiovascular patholog popul sdb examin total studi describ sdb patient cardiovascular patholog found associ sdb preval incid cardiovascular diseas pool ci pool hr ci ci notabl patient exist sdb risk new advers cardiovascular event high howev relationship cardiovascular diseas sdb like bidirect thus larg scale studi need better understand associ decid whether screen possibl sdb cardiovascular patient reason clinic signific | D002318;D012891 | T047 |
36,253,377 | sar cov antibodi respons azd vaccin west africa real world data vaccin elicit neutralis antibodi respons two dose azd african popul limit assess baselin sar cov seropreval level protect neutral antibodi prior vaccin rollout use bind antibodi analysi coupl pseudotyp virus neutralis assay two cohort west africa nigerian healthcar worker n ghanaian communiti cohort n pre post vaccin found pre vaccin particip show igg anti n posit increas respect anti receptor bind domain rbd igg specif antibodi previous igg anti n posit signific increas post two dose neutral antibodi titr popul serolog evid breakthrough infect observ neutralis antibodi observ wane popul especi anti n negat particip observ wane rate highlight need combin addit marker characteris previous infect conclud azd immunogen two independ west african cohort high background seropreval incid breakthrough infect wane titr post second dose indic need booster dose azd african set despit hybrid immun previous infect | D000086382;D014765 | T129;T047;T121;T067 |
36,253,376 | hiv cd bind site germlin antibodi env structur inform vaccin design bg vrc class broad neutral antibodi bnab hiv env relat somat hypermut shms repres promis target vaccin strategi elicit cd bind site cdbs bnab understand shms correl bg neutral hiv report singl particl cryo em structur two infer germlin igl bg precursor complex engin env base immunogen lack cdbs n glycan structur reveal critic env contact bg igl identifi antibodi light chain structur featur imped env recognit addit biochem data cryo em structur bg igl variant bound env cdbs glycan present provid insight n glycan accommod includ structur mode light chain adapt presenc n gp glycan togeth find reveal env region critic germlin antibodi recognit potenti site alter immunogen design | D015658;D015497 | T047;T005 |
36,253,375 | brain milieu induc earli microgli matur bax notch axi microglia deriv primit myeloid cell gain earli ident embryon brain howev mechan brain milieu confer microgli matur signatur remain elus demonstr bax cq zebrafish bax tmsjk mous embryo exhibit similar defect earli microgli matur bax typic pro apoptot factor high enrich neuron cell regul microgli matur pro apoptot non apoptot mechan bax regul dlb via camkii creb axi calcium depend live neuron ensur effici notch activ immigr pre microglia apoptot neuron notch signal conserv support embryon microglia matur compromis microgli develop occur cxcr cre rbpj flfl embryon mice howev microglia acquir appropri signatur incub dll vitro thus find elucid bax camkii creb notch network trigger neuron milieu microgli develop may provid innov insight target microglia neuron disord treatment | D017628;D015027 | T025;T013 |
36,253,374 | actin polymer promot invagin flat clathrin coat lattic mammalian cell push lattic edg clathrin mediat endocytosi cme requir energi input actin polymer mechan challeng condit role actin cme poor understood due inadequ knowledg actin organ clathrin coat structur ccss use platinum replica electron microscopi mammalian cell show arp complex depend branch actin network often emerg microtubul tip assembl along ccs perimet lack interact apic clathrin lattic barb end orient toward ccs structur hard compat wide held apic pull model describ actin function cme arp complex inhibit epsin knockout produc larg flat non dynam ccss split invagin subdomain upon recoveri arp inhibit moreov epsin local ccss depend arp activ propos edg push model cme wherein branch actin polymer promot sever invagin flat ccss epsin depend manner push ccs boundari thus releas forc oppos intrins curvatur clathrin lattic | D000199;D010984 | T123;T196;T116 |
36,253,373 | modular construct mil fe mil fe dual compart nanoreactor boost photocatalyt activ toward tetracyclin iron base metal organ framework mof arous extens concern prospect photocatalyst antibiot eg tetracyclin tc degrad howev effici singl simpl fe base mof still undergo restrict light absorpt weak charg separ assembl differ iron base mof build block hybrid mof mof heterostructur reactor could encourag strategi effect captur antibiot aqueous phase paper report new style mil fe mil fe photocatalyst groundbreak construct realiz doubl win boost perform adsorpt photocatalysi optic respons rang surfac open site charg separ effici mil fe mil fe regul accur design alter attribut synergist effect doubl iron base mof mil fe mil fe exhibit excel photocatalyt activ toward tc degrad compar mil fe mil fe even superior report previous literatur furthermor main activ speci h prove trap test photocatalyt process addit mil fe mil fe possess remark stabil maintain initi photocatalyt activ fifth cycl brief mil fe mil fe high effici tc degrad work offer new strategi visibl light photodegrad tc explor doubl fe base mof composit | D000073396 | T109 |
36,253,371 | small molecul inhibitor ubef crl axi induc apoptosi radiosensit lung cancer protein neddyl catalyz neddyl activ enzym nae e e conjug enzym e ligas various type human cancer neddyl pathway abnorm activ previous studi valid neddyl e ubef promis therapeut target lung cancer although nae inhibitor mlnpevonedistat current clinic investig anti cancer agent small molecul avail select target ubef report first time discoveri via structur base virtual screen chemic optim small molecul design ha ha bind ubef reduc protein level consequ inhibit cullin neddyl blockag cullin neddyl inactiv cullin ring ligas crl activ lead accumul crl substrat noxa induc apoptosi moreov ha appear form dna adduct via azaindol group induc dna damag gm arrest biolog ha effect suppress growth surviv lung cancer cell confer radiosensit vitro cell cultur vivo xenograft tumor model summari discov small molecul design ha target ubef crl axi anti cancer activ alon combin radiat | D017209;D008175 | T123;T191;T116;T043 |
36,253,370 | two dimension materi base probabilist synaps reconfigur neuron measur infer uncertainti use bayesian neural network artifici neural network demonstr superior tradit comput architectur task pattern classif learn howev measur uncertainti predict henc make wrong predict high confid detriment mani mission critic applic contrast bayesian neural network bnns natur includ uncertainti model weight repres probabl distribut eg gaussian distribut introduc three termin memtransistor base two dimension materi emul probabilist synaps well reconfigur neuron cycl cycl variat program memtransistor exploit achiev gaussian random number generat base synaps wherea memtransistor base integr circuit use obtain neuron hyperbol tangent sigmoid activ function final memtransistor base synaps neuron combin crossbar array architectur realiz bnn acceler data classif task | D016571;D013569 | T170;T030 |
36,253,369 | polar nhe swell regul migrat direct effici metastasi cell migrat regul divers patho physiolog process includ cancer metastasi accord osmot engin model polar nhe lead edg confin cell facilit water uptak cell protrus motil physiolog relev osmot engin model ident molecul mediat cell rear shrinkag remain elus demonstr nhe swell preferenti polar cell lead trail edg respect mediat cell volum regul cell dissemin spheroid confin migrat swell polar confer migrat direct effici predict mathemat determin experiment via optogenet spatiotempor regul optogenet rhoa activ cell front trigger swell distribut migrat direct revers swell express swell knockdown cell effici cell revers also requir cdc control nhe repolar dual nheswel knockdown inhibit breast cancer cell extravas metastasi vivo therebi illustr physiolog signific osmot engin model | D009369;D017923 | T123;T191;T116 |
36,253,367 | structur mitochondri ribosom fragment rrna complex membran target element mitoribosom green alga display great structur diverg tracheophyt relat fragment rrna protein defin featur report resolut structur mitoribosom alga polytomella magna harbour reduc rrna split fragment found rrna contain non canon reduc form well permut lsu domain mt rrna stabilis ml also found mitoribosom lack suggest evolutionari pathway comparison ribosom fragment rrnas observ pattern share across larg evolutionari distanc cellular compart indic evolutionari converg support concept primordi fragment ribosom protein level eleven peripher associ heat repeat protein involv bind rrna termini structur featur promin pseudo trimer one ml final exit tunnel ml constrict tunnel width vestibular area ml homolog membran target compon mediat contact inner membran bound insertas togeth structur analysi provid insight evolut ribosom machineri mitochondria | D000460;D000069396 | T026;T002 |
36,253,366 | genet model el laco magnetit apatit deposit extrus iron rich melt magnetit apatit deposit import sourc iron metal promin exampl magnetit lava el laco volcano northern chile format process remain debat test genet hypothesi fe rich melt separ silic magma ascend along collaps relat fractur complement recent analys thermodynam model corrobor fe si liquid immisc evid melt inclus el laco present viscometri fe si rich melt assess time length scale immisc liquid separ use rock deform model demonstr volcano collaps form failur zone extend toward edific flank along ore liquid ascend toward extrus driven vapour exsolut despit high densiti result support propos magmat genesi el laco deposit geochem textur similar indic magnetit apatit deposit elsewher form similar process | D052203;D007501 | T121;T197;T196;T123 |
36,253,363 | chad rsv vaccin immunogen efficaci bovin rsv infect induc diseas young calv respiratori syncyti virus rsv infect caus substanti lower respiratori tract diseas burden infant constitut global prioriti vaccin develop evalu immunogen safeti efficaci chimpanze adenovirus chad base vaccin candid chad rsv bovin rsv brsv challeng model model close reproduc pathogenesisclin manifest sever pediatr rsv diseas seroneg calv chad rsv elicit robust neutral antibodi respons human rsv two dose protect calv clinic symptomslung patholog chang reduc nasallung virus load short week long week interv last immun subsequ brsv challeng one dose regimen confer near complet signific protect short term long term interv challeng respect presenc pre exist brsv antibodi affect short term efficaci two dose regimen immun calv present clinic sign enhanc respiratori diseas collect support develop chad rsv rsv vaccin candid infant | D018357;D022261;D018112;D018113 | T129;T047;T121;T005 |
36,253,361 | therapeut strategi target host lipolysi limit infect sar cov influenza virus biosynthesi host lipid andor lipid droplet lds studi extens putat therapeut target divers viral infect howev direct target ld lipolyt catabol virus infect cell wide investig show linkag ld associ lipas activ breakdown lds generat free fatti acid ffas late stage divers rna viral infect repres broad spectrum antivir target dysfunct membran transport system due virus induc cell injuri result intracellular malnutrit late stage infect therebi make virus depend ffas generat ld storag viral morphogenesi sourc energi replic sar cov influenza virus iav suppress treatment ld associ lipas inhibitor rescu supplement ffas administr lipas inhibitor either individu combin virus target drug protect mice lethal iav infect mitig sever lung lesion sar cov infect hamster moreov lipas inhibitor signific reduc proinflammatori cytokin level lung sar cov iav challeng anim caus cytokin storm import critic infect mortal covid iav patient conclus result reveal lipas mediat intracellular ld lipolysi common exploit facilit rna virus replic furthermor suggest pharmacolog inhibitor ld associ lipas could use curb current covid futur pandem outbreak potenti troublesom rna virus infect human | D000086382;D008066;D009976 | T047;T040;T067 |
36,253,360 | local tumor microenviron acquir super enhanc induc oncogen driver colorect carcinoma tumor exhibit enhanc reprogram compar normal tissu etiolog larg attribut cell intrins genom alter use fresh resect primari crc tumor patient match adjac normal colon find diverg epigenet landscap crc tumor cell line intrigu phenomenon extend high recurr aberr super enhanc gain crc normal find one super enhanc activ epitheli cancer cell due surround inflamm tumor microenviron restor super enhanc express gene pdzkip follow treatment cytokin xenotransplant nude mice thus demonstr cell extrins etiolog demonstr mechanist pdzkip enhanc reduct capac crc cancer cell via pentos phosphat pathway show activ enabl effici growth oxid condit challeng previous notion pdzkip act tumor suppressor crc collect observ highlight signific epigenom profil primari specimen | D015179;D059016 | T191;T070 |
36,253,358 | bone marrow mesenchym stem cell deriv exosom mir p allevi renal fibrosi attenu glycolysi target pfkm renal fibrosi common patholog featur outcom almost chronic kidney diseas character metabol reprogram toward aerob glycolysi mesenchym stem cell deriv exosom msc exo propos promis therapeut approach renal fibrosi studi investig effect msc exo glycolysi under mechan demonstr msc exo signific amelior unilater uret obstruct uuo induc renal fibrosi inhibit glycolysi tubular epitheli cell tec mirna sequenc show mir p high enrich msc exo mechanist mir p repress express phosphofructokinas muscl isoform pfkm rate limit enzym glycolysi therebi attenu glycolysi tec addit knockdown mir p abolish renoprotect effect msc exo find reveal novel role msc exo suppress glycolysi provid new insight treatment renal fibrosi | D055354;D007674;D059630;D035683;D025203 | T026;T123;T025;T116;T126;T114;T047 |
36,253,353 | vesicular releas probabl set strength individu schaffer collater synaps inform process brain control quantal releas neurotransmitt tight regul process ultrastructur analysi known presynapt bouton along singl axon differ number vesicl dock activ zone clear whether probabl vesicl get releas p ves homogen also vari individu bouton optic measur evok transmitt releas individu schaffer collater synaps differ calcium concentr use genet encod glutam sensor iglusnfr fit binomi model measur respons amplitud distribut allow us extract quantal paramet n p ves q find schaffer collater bouton typic releas singl vesicl low p ves condit switch multivesicular releas high calcium salin potenc individu bouton high correl vesicular releas probabl number releas vesicl affect synapt output high p ves condit | D002118;D013572 | T026;T123;T196;T121 |
36,253,349 | systemat mendelian random use human plasma proteom discov potenti therapeut target stroke stroke second lead caus death substanti unmet therapeut need identifi potenti stroke therapeut target estim causal effect plasma protein stroke outcom two sampl mendelian random framework assess mediat effect stroke risk factor find associ genet predict plasma level six protein stroke p genet associ stroke coloc posterior probabl genet associ four protein tfpi tmprss cd cd mendelian random support atrial fibril bodi mass index smoke blood pressur white matter hyperintens type diabet stroke risk factor p bodi mass index white matter hyperintens atrial fibril appear mediat tfpi ilra tmprss associ stroke furthermor thirti six protein associ one risk factor use mendelian random result highlight causal pathway potenti therapeut target stroke | D001281;D003924;D020521 | T047;T046 |
36,253,346 | comprehens clinic accur head neck cancer organ risk delin multi institut studi accur organ risk oar segment critic reduc radiotherapi complic consensus guidelin recommend delin oar head neck h n howev prohibit labor cost caus institut delin substanti smaller subset oar neglect dose distribut oar present autom high effect stratifi oar segment soar system use deep learn precis delin comprehens set h n oar train soar use patient intern institut independ evalu extern patient across six differ institut consist outperform state art method least dice score institut evalu relat distanc error reduct crucial multi user studi demonstr soar predict need minor revis achiev clinic accept reduc workload moreov segment dosimetr accuraci within smaller inter user variat | D006258;D058958 | T191;T029 |
36,253,345 | wide spectrum neuron network phenotyp human stem cell deriv excitatori neuron rett syndrom associ mecp mutat rett syndrom rtt sever neurodevelopment disord primarili caus heterozyg loss function mutat x link gene mecp global transcript regul mutat methyl cpg bind domain mbd mecp disrupt interact methyl dna investig effect novel mecp lw missens mutat mbd atyp rtt patient preserv speech comparison sever mecp null mutat lw protein limit abil disrupt heterochromat chromocent due decreas bind dynam isol two pair isogen wt lw induc pluripot stem cell lw induc excitatori neuron express stabl protein exhibit increas input resist decreas voltag gate na k current neuron dysmorpholog limit decreas dendrit complex three isogen pair mecp null neuron expect extrem morpholog electrophysiolog phenotyp examin develop matur lw mecp null excitatori neural network activ use micro electrod array relat isogen control lw neuron increas synchron network burst frequenc contrast mecp null neuron suffer signific decreas synchron network burst frequenc transient extens network burst durat biolog motiv comput neural network model show observ chang network dynam explain chang intrins na k current individu neuron multilevel result demonstr rtt excitatori neuron show wide spectrum morpholog electrophysiolog circuitri phenotyp depend sever mecp mutat | D051783;D015518 | T123;T047;T116 |
36,253,286 | updat use ultrasound diagnosi monitor critic patient hemodynam respiratori complic main caus morbid mortal critic care unit ccu imag techniqu key tool differenti diagnosi treatment last decad ultrasound shown great potenti bedsid diagnosi respiratori diseas well hemodynam assess critic ill patient ultrasound proven use guid identifi type shock estim cardiac output guid fluid therapi vasoact drug provid secur perform percutan techniqu thoracentesi pericardiocentesi evacu abscesseshematoma detect dynam real time pulmonari atelectasi respons alveolar recruit maneuv predict wean failur mechan ventil due dynam natur simpl learn curv absenc ioniz radiat incorpor essenti tool daili clinic practic ccus object review offer global vision role ultrasound applic critic ill patient | D016638;D003422 | T047;T058 |
36,253,280 | ballist resist train similar better effect mobil non ballist exercis rehabilit peopl traumat brain injuri randomis trial peopl recov traumat brain injuri month ballist resist train program target three lower limb muscl group effect non ballist exercis rehabilit improv mobil strength balanc improv mobil translat better health relat qualiti life | D055070;D000070642 | T061;T037 |
36,253,276 | neural behavior plastic across femal reproduct cycl sex fundament evolut surviv speci howev sex also pose danger increas risk predat diseas transmiss among other thus mani speci cyclic fluctuat concentr sex hormon coordin sexual recept attract femal reproduct capac promot copul fertil possibl prevent otherwis recent decad numer studi report wide varieti sex hormon depend plastic rearrang across entir brain includ area relev femal sexual behavior contrast sex hormon induc plastic alter comput perform circuit collect produc appropri period switch femal behavior most unknown review highlight myriad sex hormon induc neuron chang known far full repertoir behavior chang across reproduct cycl exampl relationship sex hormon depend plastic neural activ behavior establish also discuss current challeng causal link action sex hormon modif specif cellular pathway behavior focus rodent model system draw comparison rodent human wherev possibl | D012726;D012098 | T081;T040;T079;T054 |
36,253,275 | neuro epitheli ilc crosstalk barrier tissu group innat lymphoid cell ilc contribut mainten mammalian barrier tissu homeostasi review ilc integr epitheli signal neurogen compon preserv tissu microenviron modul inflamm epithelium over barrier tissu includ skin lung gut generat epitheli cytokin elicit ilc activ sympathet parasympathet sensori enter fiber releas neural signal modul ilc function also highlight recent find suggest neuro epitheli ilc crosstalk implic immun inflamm resolut tissu repair restor homeostasi discuss pathogen effect disturb ilc center neuro epitheli immun cell interact putat area therapeut target | D007113;D008214 | T032;T025 |
36,253,220 | character immunogen sar cov spike protein vari glycosyl ongo coronavirus diseas covid pandem caus sever acut respiratori syndrom coronavirus sar cov drastic chang way life continu unmitig socioeconom impact across globe research potenti vaccin design product focus spike protein virus critic virus entri host cell yet whether degre glycosyl protein associ vaccin efficaci remain unclear first optim express protein mammalian cell found signific discrep puriti homogen receptor bind abil among protein deriv f cell refer f p gnti cell defect n acetylglucosaminyl transferas enzym p tn b insect cell bac p signific variat glycosyl pattern thermal stabil protein compar partial glycosyl p bac p fulli glycosyl f p exhibit higher bind reactiv convalesc sera addit f p induc higher igg neutral antibodi titr bac p mice furthermor prime boost boost regimen use combin immun p protein various degre glycosyl elicit robust neutral antibodi respons singl p alon collect studi provid insight way design effect sar cov immunogen | D064370;D000086382 | T123;T047;T116;T067 |
36,253,219 | intranas immun hrsv prefus f protein cpg adjuv elicit robust protect effect mice human respiratori syncyti virus hrsv lead caus lower respiratori tract infect elder individu young childreninf caus bronchiol even death licens hrsv vaccin ideal vaccin induc high titer neutral antibodi th bias immun respons studi use expi cell express fusion f protein prefus conform prf compar safeti efficaci intranas immun prf combin two mucos adjuv cpg odn liposom mice two intranas administr mice prf cpg group produc high titer neutral antibodi th bias immun respons compar prf lipo group lung viral load mice prf cpg group signific reduc log compar adjuv control group surviv rate surviv rate mice prf lipo group time immun strategi reduc patholog damag lung mice conclus combin prf cpg adjuv immunogen elicit th type immun respons complet protect mice lethal hrsv challeng worthi evalu hrsv vaccin clinic trial clinic trial registr studi relat human particip experiment | D018357;D022261;D018113 | T129;T047;T121;T005 |
36,253,217 | influenza subtyp specif matern antibodi protect offspr infect inhibit vaccin induc immun protect mice follow influenza virus iav infect vaccin pregnanc matern antibodi transfer offspr utero lactat age sex offspr may differenti impact transfer effect matern immun offspr evalu effect matern iav infect immun offspr intranas inocul pregnant mice subleth dose mous adapt hn mahn media mock embryon day offspr iav infect dam matern subtyp specif antibodi peak postnat day pnd remain detect pnd undetect pnd sex offspr challeng homolog iav pnd male femal offspr greater clearanc pulmonari virus less morbid mortal offspr mock inocul dam inactiv influenza vaccin iiv homolog iav pnd caus lower vaccin induc antibodi respons protect follow live virus challeng offspr iav mock infect dam effect pronounc among femal male offspr pnd impact matern infect status vaccin induc greater antibodi respons protect challeng femal male offspr iav infect mock inocul dam determin matern antibodi infect interf vaccin induc immun protect earli life offspr vaccin challeng heterosubtyp iav ie differ iav group dam pnd heterosubtyp iav matern immun affect antibodi respons iiv protect live iav challeng vaccin offspr either age subtyp specif matern iav antibodi therefor provid protect independ offspr sex interfer vaccin induc immun protect offspr pronounc effect among femal male | D007251;D053118;D009976;D007252;D009980 | T129;T121;T109;T005;T047 |
36,253,142 | chemic strategi dendrit magneto plasmon nanostructur appli surfac enhanc raman spectroscopi invit cover issu group tito trindad colleagu univers aveiro imag depict dendrit magneto plasmon substrat surfac enhanc raman scatter ser detect read full text articl chem | D013059;D049329 | T070;T059;T073 |
36,253,132 | propag diffus weight mri abnorm preclin stage sporad creutzfeldt jakob diseas current establish biomark exist presymptomat sporad creutzfeldt jakob diseas scjd purpos studi rais awar scjd case show abnorm brain mri diffus weight imag dwi symptom onset demonstr tempor chang dwi abnorm preclin period | D007562 | T047 |
36,253,113 | contact general practic covid pandem regist base studi covid pandem alter provis health care expand telehealth consult | D000086382;D058006;D017216 | T047;T058;T091;T067 |
36,253,107 | metabolit control ubiquitin conjugas ubc promot mitochondri protein import mitochondria play key role cellular energi metabol transit glycolyt respiratori condit induc consider adapt cellular proteom metabol depend chang particular pronounc protein composit mitochondria show yeast cytosol ubiquitin conjugas ubc play crucial role remodel process cell transit respiratori ferment condit ubc conserv well studi compon catabolit control system known regul stabil gluconeogen enzym unexpect found ubc also promot assembl translocas outer membran mitochondria tom increas level cytosol expos receptor subunit tom ubc defici result compromis protein import mitochondria reduc steadi state level mitochondri protein observ show ubc control prevail metabol condit promot switch glucos synthesi glucos usag cytosol induc biogenesi mitochondri tom machineri improv mitochondri protein import phase metabol transit | D029701;D044763;D021381 | T126;T116;T044;T043 |
36,253,099 | emerg structur pharmacolog atp sensit potassium channel atp sensit potassium channel k atp energi sensor particip rang physiolog process channel also clinic valid drug target decad k atp inhibitor prescrib diabet k atp activ use treatment hypoglycemia hypertens hair loss emerg concept articl highlight current knowledg drug bind mode observ use cryogen electron microscopi techniqu inhibitor activ bind two distinct site transmembran domain sulfonylurea receptor sur subunit also discuss possibl mechan drug alloster modul dimer sur nucleotid bind domain nbds thus k atp channel activ signific statement atp sensit potassium channel k atp fundament energi homeostasi particip mani vital physiolog process k atp channel import drug target k atp inhibitor insulin secretagogu k atp activ broad use clinic treatment relat diseas recent cryogen electron microscopi studi allow us understand emerg concept k atp structur pharmacolog | D061385;D024661 | T121;T116;T123 |
36,253,067 | panoptosi uniqu innat immun inflammatori cell death modal innat immun first respons protect pathogen cellular insult pattern recognit receptor sens pathogen damag associ molecular pattern induc innat immun respons character inflamm program cell death pcd depth character innat immun pcd pathway highlight signific cross talk recent advanc led identif uniqu inflammatori pcd modal call panoptosi regul multifacet panoptosom complex assembl integr compon pcd pathway total biolog effect observ panoptosi account pcd pathway alon review briefli describ mechan innat immun cell death includ molecular mechan panoptosi activ regul also highlight panoptosom identifi date provid overview implic panoptosi diseas therapeut target improv understand innat immun mediat cell death panoptosi critic inform next generat treatment strategi | D017209;D007113 | T123;T032;T116;T043 |
36,253,064 | innov hospit tomorrow hospit tomorrow must aim innov establish also becom establish innov object bring initi express need hospit communiti evalu priorit implement select project | D006761 | T073;T093 |
36,253,063 | digit contribut improv modern healthcar system modern develop inform system major challeng hospit futur driven public author hpital numriqu ouvert sur son environn digit hospit open environ program sgur digit health program reli digit technolog facilit exchang share inform thus improv qualiti servic provid user term care support treatment nation agenc support perform health medic social establish yves beauchamp work propos tool methodolog kit help establish achiev object set nation program | D003695;D006761 | T058;T073;T093 |
36,253,062 | citi hospit link base characterist target popul need strengthen citi hospit network intend improv respons need peopl move back forth healthcar system douard habib director fdration rgional des dispositif de ressourc et dappui la coordin des parcour de sant dle de franc mari dominiqu lussier geriatrician expert field health care pathway discuss way achiev goal particular specifi import think term target popul consid network meta organ capabl adapt chang need transform digit tool vector network | D003695;D006301 | T058;T098;T093;T080 |
36,253,061 | place user famili tomorrow healthcar system partnership health innov concept bring chang part attempt synthes support practic action polit citizen scope applic pose challeng issu actor tomorrow health system | D003695 | T058;T093 |
36,253,060 | effect deploy artifici intellig healthcar profess understand effect spread artifici intellig robot healthcar profess must free prejudic way possibl promot real methodolog evalu support transform | D001185;D003695 | T090;T073;T093;T066;T058 |
36,253,059 | collabor project improv emerg room admiss codesign design project approach gradual open hospit sector ambit contribut improv hospit benefit patient caregiv challeng taken univers hospit montpelli creat experiment project integr design practic emerg room | D004636;D006761 | T073;T093 |
36,253,058 | engag health medico social institut sustain develop csr approach health medico social establish everi interest embark corpor social respons establish decarbonis complianc regul attract strategi link territori partner econom interest etc support fdration hospitalir de franc put forward propos presidenti candid intend support throughout emmanuel macron new five year term | D012941;D000076502 | T078;T068;T067;T054 |
36,253,057 | transform univers hospit maintain tripl mission care teach research univers hospit demonstr effect sinc creation risen challeng expertis research care teach also challeng respons toward health territori serv context health crisi prompt confirm commit encourag continu evolut model combin care research teach | D006785 | T073;T093 |
36,253,048 | evalu implement diabet self manag educ maryland counti liberia protocol pilot prospect cohort studi achiev glycaem target peopl live diabet plwd challeng especi set limit resourc programm need address gap knowledg skill self manag diabet self manag educ dsme evid base intervent educ empow plwd improv self manag activ protocol describ pilot studi assess feasibl accept effect clinic outcom implement dsme clinic care peopl live insulin depend diabet liberia | D003924;D061385;D000073278 | T121;T047;T058 |
36,253,047 | cross section studi covid relat mortal predictor brazilian state wide landscap role demograph factor symptom comorbid brazilian state paran suffer covid effect understand predictor increas mortal health system intervent prevent hospitalis patient select best model evalu associ death demograph characterist symptom comorbid base three level clinic sever covid non hospitalis hospitalis non icu ward icu ward | D000086382 | T047;T067 |
36,253,046 | domest abus sibl studi dasi multimethod studi protocol domest violenc abus dva everyday aspect mani children young peopl live home relationship studi estim one million children young peopl experi form dva year uk although major famili experienc dva one child research date focus individu children within famili studi aim explor view practition parentcar young peopl sibl respons context aftermath dva protocol follow spirit guidelin | D002649;D017579 | T054;T048 |
36,253,045 | preterm birth prescript cardiovascular antiseizur antibiot antiasthmat medic children year age popul base data linkag cohort studi across six european region preterm children expos mani medic neonat intens care unit littl known effect prematur medic use throughout infanc childhood examin prescript cardiovascular medic cvm antiseizur medic asm antiasthmat medic antibiot issueddispens first year life moder preterm children compar term | D018927;D047928 | T121;T046 |
36,253,044 | impact covid pregnanc relat healthcar utilis prospect nationwid registri studi assess impact covid pregnanc relat healthcar utilis differ across social group | D000086382;D010342;D011295 | T067;T080;T055;T047;T058 |
36,253,043 | quantifi antibiot use typhoid fever india cross section analysi privat sector medic audit data estim antibiot prescript rate typhoid india | D015363;D014435 | T047;T109 |
36,253,042 | effect function relax qualiti life patient periprosthet joint infect protocol randomis control trial periprosthet joint infect pji devast complic orthopaed trauma surgeri put high burden patient involv recurr hospitalis prolong cours antibiot medic sever pain long period immobl well high level psycholog distress thus multicentr studi aim implement bodi orient psychotherapi clinic practic evalu therapeut effect qualiti life | D000086382;D016459 | T047;T046;T067 |
36,253,041 | effect structur rehabilit versus non structur rehabilit follow non surgic manag displac proxim humerus fractur protocol randomis clinic trial increas number patient displac proxim humerus fractur phf offer non surgic treatment includ short immobilis structur rehabilit randomis control trial rcts compar structur rehabilit non structur rehabilit investig benefit structur rehabilit | D019637;D012784 | T061;T037 |
36,253,040 | high dose enter docosahexaeno acid omega supplement prevent bronchopulmonari dysplasia preterm infant protocol systemat review meta analysi docosahexaeno acid dha supplement neonat period propos prevent bronchopulmonari dysplasia bpd preterm infant aim determin effect enter supplement high dose dha risk bpd week postmenstru age pma preterm infant born less week gestat compar control | D001997;D007235 | T047 |
36,253,039 | use primari care data assess compar effect safeti apixaban rivaroxaban patient nonvalvular atrial fibril uk observ cohort studi compar real world effect safeti direct oral anticoagul doac patient nonvalvular atrial fibril afib prevent stroke | D001281;D002546;D009203;D020521 | T047;T046 |
36,253,038 | perceiv qualiti care among household ever enrol communiti base health insur scheme two district northeast ethiopia communiti base cross section studi examin client perceiv qualiti healthcar receiv identifi associ factor individu facil level | D000080051 | T058 |
36,253,037 | effect social prescrib link worker health outcom cost adult primari care communiti set systemat review establish evid base effect health outcom cost social prescrib link worker non health social care profession connect peopl communiti resourc peopl communiti set focus peopl experienc multimorbid social depriv | D011788;D000068217 | T078;T097 |
36,253,036 | sexual harass covid pandem among adolesc girl young women agyw nairobi kenya cross section studi sexual harass among adolesc girl young women agyw preval understudi form gender base violenc gbv negat impact health well covid pandem rais global concern gbv within home less known affect gbv public space | D000086382;D015658;D017406 | T054;T047;T067 |
36,253,035 | factor associ perceiv coercion adult receiv psychiatr care scope review protocol coercion inevit link psychiatr mental healthcar though mani form coercion exist perceiv coercion appear less studi form despit mark preval negat consequ literatur sever factor studi associ perceiv coercion literatur review focus precis subject gain knowledg associ factor degre perceiv coercion essenti guid futur research develop inform intervent purpos review identifi literatur factor associ perceiv coercion adult receiv psychiatr care | D003068;D012107 | T062;T170;T096;T054;T081;T169 |
36,253,034 | support self manag women pre exist diabet pregnanc protocol mix method sequenti compar case studi women pre exist type type diabet glycaem target narrow preconcept prenat period optimis pregnanc outcom women aim achiev glycaem target pregnanc daili task diabet self manag diabet self manag pregnanc involv frequent self monitor blood glucos titrat insulin base glucos measur carbohydr intak object explor self manag support experi help explain glycaem control among women pre exist diabet pregnanc | D003924;D000073278 | T047;T058 |
36,253,033 | comparison primari cytolog primari hpv test co test cervic cancer screen chines women popul base screen cohort compar clinic perform three strategi primari human papillomavirus hpv test primari cytolog co test cervic cancer screen | D052685;D018290;D030361;D002583 | T005;T191;T047 |
36,253,031 | recent advanc futur perspect use machin learn mathemat model nephrolog review latest advanc use mathemat model nephrolog look distinct categori mathemat model wide use biolog research point strength weak appli health care especi context nephrolog mechanist dynam system allow represent causal relat among system variabl complex longer developmentimplement phase artifici intelligencemachin learn provid predict tool allow identifi correl pattern larg data set usual harder interpret black box chronic kidney diseas ckd major worldwid health problem generat copious quantiti data leverag choic appropri model also larg number dialysi paramet need determin everi treatment session benefit predict mechanist model follow import step use mathemat method medic scienc might intersect seem antagonist framework leverag strength provid better care | D009398 | T091 |
36,253,030 | natur languag process nephrolog unstructur data electron health record contain essenti patient inform natur languag process nlp teach comput read allow us tap data without need time effort manual chart abstract core first step nlp algorithm preprocess text identifi core word differenti text filter nois tradit nlp use rule base approach appli grammat rule infer mean text newer nlp approach use machin learningdeep learn infer mean without explicit program nlp use nephrolog research focus identifi distinct diseas process ckd extract patient orient outcom symptom high sensit nlp identifi patient featur clinic text associ acut kidney injuri progress ckd last inclus featur extract use nlp improv perform risk predict model compar model use structur data implement nlp algorithm slow partial hinder lack extern valid nlp algorithm howev nlp allow extract key patient characterist free text infrequ use resourc nephrolog | D009398;D051436 | T047;T091 |
36,253,028 | artifici intellig acut kidney injuri predict use artifici intellig ai nephrolog associ clinic research grow recent year seen increas interest util ai predict develop hospit base acut kidney injuri aki sever ai techniqu employ improv abil detect aki across varieti hospit set review discuss evolut aki risk predict discuss static risk assess model yesteryear well recent trend toward ai advanc learn techniqu discuss relat improv aki detect well relat dearth data around clinic implement patient outcom use model use ai aki detect clinic care infanc review describ arriv current posit hint promis futur | D058186;D009398 | T047;T091;T037 |
36,253,027 | artifici intellig assist deliv continu renal replac therapi continu renal replac therapi crrt wide util support critic ill patient acut kidney injuri artifici intellig ai potenti enhanc crrt deliveri evid limit review exist literatur util ai crrt object identifi current gap evid research consider conduct scope review focus develop use ai base tool patient receiv crrt ten paper identifi publish focus machin learn model augment crrt deliveri innov designear valid phase develop primari research interest focus earli indic crrt need prognost mortal kidney recoveri identif risk factor mortal secondari research prioriti includ dynam crrt monitor predict crrt relat complic autom data pool point care analysi literatur gap includ prospect valid implement bias ascertain evalu ai generat health care dispar research ai applic enhanc crrt deliveri grown exponenti last year field remain prematur need evalu applic could enhanc bedsid decis make capac assist structur process crrt deliveri | D058186;D000079664 | T061;T047;T037 |
36,253,026 | machin learn acut kidney injuri predict intens care unit machin learn field artifici intellig comput train make predict identifi pattern data complex mathemat algorithm great potenti critic care predict outcom acut kidney injuri use prognosi suggest manag strategi machin learn also use research tool advanc clinic biochem understand acut kidney injuri review introduc basic concept machin learn review recent research domain | D058186;D001185 | T090;T073;T066;T037;T047 |
36,253,025 | practic implement challeng artifici intellig driven electron health record evalu protect health inform detect protect health inform electron health record system often earli step health care analyt nontrivi problem specif challeng includ find clinician name diseas lack fix format often context depend general problem find entiti term name entiti recognit receiv substanti amount attent natur languag process deep learn communiti paper begin outlin recent method find protect health inform introduc hybrid system combin regular express natur languag process framework call flair flair open sourc includ state art deep learn model support straightforward develop new model languag task includ name entiti recognit final discuss appli system structur text databas tabl well unstructur text clinic note | D001185;D057286 | T090;T170;T073;T066 |
36,253,020 | self manag programm activ cope educ space copd c primari care pragmat randomis trial previous develop support self manag programm smp self manag programm activ cope educ chronic obstruct pulmonari diseas copd success deliv individu basi payer express interest deliv intervent group | D029424;D000073278 | T047;T058 |
36,253,018 | simplifi dose oral azithromycin children month old child surviv programm age base height base dose protocol facilit mass distribut azithromycin trachoma control programm use height instead weight determin dose children month year old recommend azithromycin distribut children month old reduc mortal high mortal set care monitor condit weight use determin dose children month old studi azithromycin distribut child surviv simplifi approach use age height age month old could increas programm effici real world set | D017963;D014141 | T047;T195;T109 |
36,253,017 | adolesc birth rate urban social environ latin american citi latin america second highest adolesc birth rate abr worldwid variat urban rural area evid link countri develop abr point toward upstream factor causal pathway investig variat abr within citi whether differ featur urban social environ associ abr | D001723;D012931 | T081;T068;T078 |
36,253,016 | explor variat qualiti care clinic outcom neonat unit novel use uk nation neonat audit programm nnap neonatolog relat new specialti much practic remain non evid base variat qualiti care deliv recognis measur challeng one possibl indic variat practic decad nation neonat audit project nnap describ variat practic uk neonat unit relat annual review audit measur base evid base nation standard develop consensus method becom de facto measur defin good qualiti neonat healthcar within uk articl explor practic use nnap look associ qualiti care outcom would valid measur could help toward better understand reason under recognis variat outcom even neonat unit design | D007363;D012107 | T073;T093;T062;T096;T170;T081;T169 |
36,253,015 | hcahp constant communic augment hospit patient satisfact hospit consum assess healthcar provid system hcahp becom standardis instrument measur hospitalis patient percept care hospit hcahp score communic doctor domain medic servic suboptim compar peer group decemb goal improv perform communic doctor domain least baselin month period | D003142;D017060 | T054;T170;T097;T080 |
36,253,014 | metabolom marker glucos regul lifestyl intervent prediabet disentangl specif factor regul glycemia prediabet normoglycemia could improv type diabet prevent strategi metabolom provid substanti insight biolog understand environment factor diet studi aim identifi metabolom marker regress normoglycemia context lifestyl intervent lsi individu prediabet | D003924;D011236 | T047 |
36,253,013 | manag life threaten fluorouracil cardiotox fluorouracil fu known cardiotoxin backbon treatment colorect cancer associ arrhythmia myocardi infarct sudden cardiac death common associ coronari vasospasm secondari direct toxic effect vascular endotheliuma woman metastat colon cancer origin treat fu infus part folfiri folin acid fluorouracil irinotecan regimen unabl toler chemotherapi due chest pain transit infusion fu inferior hour bolus fu attempt minimis cardiotox diseas progress multidisciplinari decis made trial fu infus pretreat diltiazem toler chemotherapi without advers event multidisciplinari discuss recommend co manag revers fu associ cardiotox coronari arteri diseas cad risk stratif treatment empir treatment calcium channel blocker andor nitrat may allow patient suspect coronari vasospasm fu continu vital chemotherapi | D015179;D003329 | T047;T191 |
36,253,012 | recurr pleomorph adenoma unusu caus isol sphenoid sinus lesion pleomorph adenoma common benign salivari gland tumour head neck region common seen parotid gland may aris also minor salivari gland upper aerodigest tract compris upper lip cheek floor mouth rare mucoser gland nasal caviti paranas sinus middl age man undergon surgeri nasal mass year ago present headach visual complaint recurr mass origin sphenoid sinus isol sphenoid sinus space occupi lesion alway diagnost challeng mass biopsi diagnos pleomorph adenoma histopatholog excis endoscop earli accur diagnosi biopsi may result complet excis tumour prevent recurr endoscop rout prefer surgic excis patient follow clinic radiolog detect earli recurr | D008949;D012468 | T191 |
36,253,011 | spontan retroperiton haemorrhag pancreatoduoden arteri pda ruptur associ complic spontan retroperiton haemorrhag srh rare may present abdomin back pain without haemodynam instabl aggress resuscit investig caus bleed provid haemostasi standard care subsequ close monitor necessari identifi earli complicationsthi studi report three patient present institut within last year srh ruptur pancreaticoduoden arteri pda aneurysm patient uniqu present complic treatment demonstr variabl complex srh one patient present sudden abdomin pain hypovolaem shock underw angioembolis event recoveri anoth patient present similar treat via angioembolis experienc gastric outlet obstruct obstruct jaundic requir surgic haematoma evacu anoth patient incident find haemoperitoneum laparoscop cholecystectomi subsequ diagnos srh result pda aneurysm ruptur secondari medial arcuat ligament syndrom | D017542 | T047 |
36,253,010 | bilater atraumat femor neck fractur result transient osteoporosi hip woman mid present orthopaed team unabl mobilis short caesarean section question report week atraumat right hip pain radiograph reveal displac right subcapit neck femur fractur mri confirm well identifi minim displac left subcapit neck femur fractur underw right total hip replac intern fixat left hip dual energi x ray absorptiometri dexa scan show sever osteoporosi diagnosi transient osteoporosi hip made seen bone metabol team given calcium vitamin medic although atraumat hip fractur rare young patient disproportion persist hip pain pregnant patient rais index suspicion prompt investig form mri allow time manag hip fractur improv patient outcom | D005264;D005265;D006620;D010024 | T047;T037 |
36,253,009 | reward motiv memori influenc new learn across develop previous reward experi influenc choic new situat past work demonstr exist reward associ either help hinder futur behavior substanti individu variabl transfer valu across context development chang reward sensit may also modul impact prior reward associ later goal direct behavior current studi aim character reward associ form past affect learn present childhood adulthood particip complet reinforc learn paradigm use high low reward stimuli task complet h earlier well novel stimuli choic option found prior high reward associ imped learn across age assess individu differ priorit high versus low reward associ memori impact new learn greater high reward memori priorit associ wors learn perform previous high reward relat low reward stimuli across age adolesc also show imped earli learn regardless individu differ high reward memori priorit detriment effect previous reward choic behavior persist beyond learn find indic prior reward associ proactiv interfer futur learn childhood adulthood individu differ reward relat memori priorit influenc new learn across age | D012054;D012201 | T061;T041 |
36,253,008 | decreas associ process memori confid aphantasia visual imageri mental reconstruct scene consid core compon episod memori retriev individu absent visual imageri aphantasia score lower test autobiograph memori suggest aphantasia may associ differ episod associ process onlin studi test aphantas particip control associ recognit memori confid three type associ encod incident associ visual visual audio visual stimulus pair associ object locat screen intraitem associ aphantas particip lower rate high confid hit associ memori test compar control perform auditori visual associ correl individu differ measur object imageri aphantas group control overal group differ memori perform found indic visual imageri select contribut memori confid analysi encod task reveal aphantas made fewer associ link stimuli suggest role visual imageri associ process visual auditori input data enhanc understand visual imageri contribut associ memori character cognit profil aphantasia | D007092;D061212 | T041 |
36,253,007 | target memori reactiv sleep induc forget overlap memori memori reactiv sleep shape new memori long term form reactiv memori induc via deliveri auditori cue sleep although target memori reactiv tmr approach strengthen newli acquir memori research tend focus singl associ memori less clear tmr affect retent overlap associ memori critic given repeat retriev overlap associ wake lead forget phenomenon known retriev induc forget rif ask whether similar pattern forget occur tmr use cue reactiv overlap pairwis associ sleep particip learn overlap pair learn separ interleav unrel pair sleep cu subset overlap pair use tmr tmr increas retent first encod pair memori decreas second encod pair pattern retent present pair test prior sleep result suggest tmr lead forget effect similar rif wake howev effect extend memori strengthen via retriev prior sleep therefor provid evid reactiv induc forget effect sleep | D000069077;D012890 | T033;T040;T041 |
36,253,006 | social enrich environ test new approach evalu social behavior mous model social anxieti disord social anxieti disord sad common anxieti disord character mark fear social situat treatment sad includ exposur therapi medic satisfactori patient led develop sever paradigm studi social fear rodent howev still social impair observ sad patient never examin rodent model inde social situat avoid sad patient includ social interact also public perform observ other nevertheless test use assess sociabl rodent evalu most social interact pair thus develop new test social enrich environ test evalu sociabl within group three unfamiliar conspecif enrich environ studi induc sad like behavior ie social fear male mice use social fear condit sfc test social fear use social enrich environ test three chamber test final test effect fear extinct acut diazepam treatment revers social fear result reveal condit mice decreas object explor proxim conspecif social interact mous like object explor extinct train acut diazepam treatment revers sfc induc behavior chang find demonstr social enrich environ test provid appropri behavior approach better understand etiolog sad test may also import implic explor new treatment | D000072861 | T048 |
36,253,002 | local ablat immunotherapi drive de novo cd cell respons poor immunogen tumor local ablat immunotherapi hold great promis stimul antitumor immun treat metastat poor immunogen tumor tumor ablat well known releas tumor antigen danger associ molecular pattern stimul cell immun immun stimul effect limit particular metastat tumor | D018414;D008546 | T191;T050;T025 |
36,253,001 | efficaci cetuximab plus pd inhibitor differ hpv status head neck squamous cell carcinoma systemat review meta analysi addit cetuximab signific increas antitumor effect program cell death protein pd inhibitor recurr metastat head neck squamous cell carcinoma hnscc howev preliminari analys suggest human papillomavirus hpv posit diseas benefit less hpv negat diseas therefor conduct meta analysi assess whether efficaci combin therapi vari accord hpv status hnscc | D006258;D030361 | T047;T191 |
36,253,000 | pd ltlr dual target nanobodi drug conjug mediat potent tumor regress via elev tumor immunogen host express pd l bias depend way various tumor insensit immun checkpoint blockad icb therapi toll like receptor tlrs establish link innat adapt immun assist cell activ serv promis target combin enhanc icb therapi aim improv efficaci anti program death ligand pd l therapi develop pd ltlr dual target nanobodi drug conjug ndc base pd l nanobodi tlr agonist develop | D009369;D061905 | T129;T191;T116 |
36,252,999 | ige type multipl myeloma exhibit hypermut phenotyp tumor reactiv cell multipl myeloma mm hematolog malign origin malign clonal expand plasma cell mm molecular stratifi clonal evolut deciph base ig heavi light chain respect malign plasma cell clone mm subtyp ige type mm account lt case associ aggress clinic cours consequenti dismal prognosi malign adopt transfer autolog lymphocyt specif target present neo epitop encod either somat mutat specif overexpress gene result substanti object clinic regress even relapsedrefractori diseas howev data genet immunolog characterist rare aggress entiti comprehens profil ige type kappa mm genom immun repertoir level integr dna singl cell rna sequenc compar profil non ige type mm sampl demonstr distinct pathophysiolog mechan well novel opportun target ige type mm data provid rational patient individu neoepitop target cell therapi high tumor mutat burden mm | D009101 | T191 |
36,252,998 | phase ib studi pembrolizumab combin trastuzumab emtansin metastat posit breast cancer preclin clinic data support potenti synergi anti therapi plus immun checkpoint blockad safeti toler trastuzumab emtansin dm combin pembrolizumab unknown | D001943 | T191 |
36,252,997 | immunosuppress lncrna linc promot tumor progress therapi resist adar stabil despit success target therapi achiev prolong surviv approxim treat individu treatment resist still import challeng breast cancer bc patient influenc adapt innat immun respons therapeut outcom herbc patient extens demonstr | D000243;D062085;D016601 | T123;T126;T116;T114 |
36,252,996 | evalu tumor microenviron biomark immun checkpoint inhibitor respons metastat renal cell carcinoma immunotherapi combin includ ipilimumab nivolumab standard care untreat metastat renal cell carcinoma mrcc biomark respons lack predict patient favor unfavor respons immunotherapi studi aim use omniseq transcriptom base platform develop biomark respons immunotherapi | D002292;D007680 | T191 |
36,252,995 | tumor microenviron show immunolog abscop effect patient nsclc treat pembrolizumab radiotherapi combin immunotherapi current part standard care patient advanc stage non small cell lung cancer nsclc howev mani patient respond treatment therefor combin strategi explor increas clinic benefit pembro rt trial combin therapeut program cell death pd antibodi pembrolizumab stereotact bodi radiat therapi sbrt increas overal respons rate studi effect tumor microenviron tme | D002289;D008175 | T191 |
36,252,994 | lipoprotein level global popul establish atherosclerot cardiovascular diseas lipoprotein lp import genet determin risk factor atherosclerot vascular diseas ascvd develop lp lower therapi studi sought characteris pattern lp level global ascvd popul identifi racial ethnic region gender differ | D050197;D002545;D002318;D020521 | T047;T046 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.